GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Modalis Therapeutics 4883.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

26

+8.33%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

—

FY2018FY2025

Net income

−¥2.15bn

FY2018FY2025

Free cash flow

−¥2.12bn

FY2018FY2025

Shareholders' equity

¥2.79bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue———¥40.5m¥1.1m¥342.0m¥644.0m¥65.3m
Research and development¥1.98bn¥1.90bn¥2.10bn¥1.86bn¥1.01bn¥531.9m¥303.0m¥217.9m
Operating income−¥2.21bn−¥1.34bn−¥2.37bn−¥2.70bn−¥745.4m−¥439.5m¥157.0m−¥214.1m
Net income−¥2.15bn−¥1.32bn−¥2.39bn−¥2.70bn−¥739.0m−¥448.4m¥140.0m−¥217.9m
Diluted earnings per share-24.20-28.66-74.94-92.59-25.51-15.721.48-2.31

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets¥2.96bn¥3.69bn¥2.03bn¥3.13bn¥6.07bn¥6.28bn¥3.94bn¥1.22bn
Cash and short-term investments¥2.81bn¥3.58bn¥1.88bn¥2.93bn¥4.94bn¥5.42bn¥3.86bn¥1.21bn
Total liabilities¥170.9m¥143.5m¥645.5m¥188.6m¥519.9m¥70.2m¥15.2m¥22.7m
Debt——¥412.5m—————
Shareholders' equity¥2.79bn¥3.55bn¥1.38bn¥2.94bn¥5.55bn¥6.21bn¥3.84bn¥1.20bn
Shares outstanding89m46m32m29m29m29m94m94m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−¥2.12bn−¥1.43bn−¥2.25bn−¥1.90bn−¥747.5m−¥376.6m¥224.1m−¥376.0m
Capital spending−¥2.6m−¥188,000−¥39.7m−¥197.3m−¥107.1m−¥830.0m−¥54.3m−¥16.0m
Free cash flow−¥2.12bn−¥1.43bn−¥2.29bn−¥2.09bn−¥854.6m−¥1.21bn¥169.9m−¥392.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−¥657.8m−¥342.5m−¥396.8m−¥783.1m−¥399.1m−¥632.9m−¥275.3m−¥223.4m
Net income−¥596.5m−¥323.7m−¥350.9m−¥781.3m−¥368.2m−¥652.2m−¥257.7m−¥279.3m
Diluted earnings per share-6.32-3.43-3.95-8.78-4.14-7.33-5.60-6.07
Total assets¥3.14bn¥2.94bn¥2.96bn¥3.42bn¥3.42bn¥3.68bn¥3.69bn¥2.81bn
Cash and short-term investments¥3.02bn¥2.81bn¥2.81bn¥3.31bn¥3.26bn¥3.56bn¥3.58bn¥2.70bn
Debt¥270.0m——¥262.5m————
Shareholders' equity¥2.46bn¥2.80bn¥2.79bn¥2.69bn¥3.19bn¥3.31bn¥3.55bn¥2.51bn

Financial ratios

Data as of 15 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin———-6684.0%-67765.2%-128.5%24.4%-327.7%
Net margin———-6673.4%-67177.8%-131.1%21.7%-333.7%
Return on equity-77.1%-37.1%-173.3%-91.9%-13.3%-7.2%——
Return on assets-72.6%-35.7%-118.1%-86.4%-12.2%-7.1%——
Free cash flow yield-84.9%-111.2%-247.8%-207.8%-79.0%56.8%——
Revenue growth———3581.8%-99.7%-46.9%886.3%—
Earnings growth63.3%-44.9%-11.5%265.7%64.8%-420.3%——
Current ratio21.46x30.83x9.88x21.58x28.04x93.51x——
Debt to equity—0.00x0.30x0.00x0.00x0.00x——
Equity ratio94.2%96.1%68.1%94.0%91.4%98.9%——
Interest coverage-766.18x-234.43x-537.98x-561.28x-683.87x-26.84x——
R&D as a share of sales———4596.8%91774.8%155.5%47.0%333.7%
Buybacks as a share of market value-93.4%-44.1%-9.3%-0.8%-1.6%———

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-6.4%38.1%—
Net income-7.3%36.9%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-2.3-3.6-1.6-3.6-24.0-140.7
Price to sales———241.4—184.4

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.